Results 1 to 10 of about 854 (146)

Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies

Neurology and Therapy, 2020
Introduction Migraine is associated with substantial functional impairment and affects many aspects of daily life. Methods Using data from SAMURAI and SPARTAN (double-blind, placebo-controlled, phase 3 studies) and GLADIATOR (an open-label, phase 3 study
Timothy Smith, John H. Krege, Suchitrita S. Rathmann, Sherie A. Dowsett, Ann Hake, Emel S. M. Nery, Brandy R. Matthews, Erin G. Doty   +7 more
doaj   +2 more sources

Lasmiditan for the treatment of acute attack of migraine: Systematic review and meta-analysis of randomized controlled trials

National Journal of Physiology, Pharmacy and Pharmacology, 2022
Background: Acute migraine is the most common disabling chronic neurological disorder in the world. There are a huge proportion of unmet needs in treatment efficacy and satisfaction with currently available drugs and hence need for newer agents. One such
Sharanabasayyaswamy Basayya Hiremath, Srinivas Lokikere Devendrappa   +1 more
doaj   +1 more source

Efficacy of 5-HT1F agonist versus CGRP-antagonists for treatment of acute migraine: A systematic review and network meta-analysis

National Journal of Physiology, Pharmacy and Pharmacology, 2023
Background: Two new classes of drugs approved by USFDA for the treatment of acute migraine are non-peptide Calcitonin Gene-Related Peptide (CGRP) receptor antagonists (rimegepant and ubrogepant) and 5-HT1F receptor agonist lasmiditan.
Sharanabasayyaswamy Basayya Hiremath, Srinivas Devendrappa Lokikere   +1 more
doaj   +1 more source

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)

BMC Neurology, 2019
Background We studied the efficacy and safety of a second dose of lasmiditan for acute treatment of migraine. Methods SAMURAI and SPARTAN were double-blind, placebo-controlled Phase 3 studies in which individuals with migraine were randomized to oral ...
Li Shen Loo, Brian M. Plato, Ira M. Turner, Michael G. Case, Joel Raskin, Sherie A. Dowsett, John H. Krege   +6 more
doaj   +1 more source

Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study

The Journal of Headache and Pain, 2020
Background Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT1F receptor agonist developed for acute treatment of migraine.
Richard B. Lipton, Louise Lombard, Dustin D. Ruff, John H. Krege, Li Shen Loo, Andrew Buchanan, Thomas E. Melby, Dawn C. Buse   +7 more
doaj   +1 more source

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

The Journal of Headache and Pain, 2022
Background In the absence of head-to-head trials, comprehensive evidence comparing onset of efficacy of novel agents for acute treatment of migraine is lacking.
Pepa Polavieja, Mark Belger, Shiva Kumar Venkata, Stefan Wilhelm, Erin Johansson   +4 more
doaj   +1 more source

Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

The Journal of Headache and Pain, 2019
Objective To study the efficacy and safety of lasmiditan for acute treatment of migraine in patients using migraine preventive medications. Background While lasmiditan has been proven to be an effective acute treatment for migraine, its effectiveness has
Li Shen Loo, Jessica Ailani, Jack Schim, Simin Baygani, Hans-Peter Hundemer, Martha Port, John H. Krege   +6 more
doaj   +1 more source

Long-term safety and efficacy of lasmiditan for acute treatment of migraine: Final results of the GLADIATOR study

Cephalalgia Reports, 2020
GLADIATOR was a prospective, randomized, open-label, phase 3 study of lasmiditan 100 mg or 200 mg dosed intermittently for up to 1 year in patients with episodic migraine. Most patients had completed one of two single-attack studies before participation.
Jan Lewis Brandes, Suzanne Klise, John H Krege, Michael Case, Rashna Khanna, Raghavendra Vasudeva, Joel Raskin, David Kudrow   +7 more
doaj   +1 more source

Serotonin receptor agonist and risk of paresthesia in migraine patients: A dose-response model-based (network) meta-analysis

Annals of Indian Academy of Neurology, 2022
Background: Migraine may be an important factor for paresthesia in the limbs, especially in the upper limbs. In several patients, paresthesia is responsible for a low quality of life.
Sayed Aliul Hasan Abdi, Shabihul Fatma Sayed, Jamuna Bhaskar   +2 more
doaj   +1 more source

Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis

The Journal of Headache and Pain, 2020
Background Migraine has been recognized as one of common diseases in the world whose current treatment options are not ideal. Lasmiditan, an oral 5-hydroxytryptamine (HT)1F receptor agonist, appears more promising for the acute treatment of migraine ...
Min Hou, Haiyan Xing, Chen Li, Xianfeng Wang, Dongmei Deng, Juan Li, Pan Zhang, Jianhong Chen   +7 more
doaj   +1 more source